Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




Feb
25
Today In Oncology
FDA Approves Encorafenib for Metastatic BRAF V600E–Mutated Colorectal Cancer
MRI-Based Neoadjuvant Chemotherapy Duration in HER2-Positive Breast Cancer
Can a New Testing Method Allow More Patients With Bladder Cancer to Avoid Radical Cystectomy
Adjuvant Coformulated Vibostolimab Plus Pembrolizumab in High-Risk Stage IIB to IV Melanoma
Microplastics Found in 90 Percent of Prostate Cancer Samples
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo